At Accellta, we’re revolutionizing the future of biotechnology. Since 2012, under the leadership of globally recognized stem cell expert Dr. Michal Amit, we’ve been at the forefront of transforming cell culture. As a company founded and managed primarily by women, we take pride in shaping a more inclusive and innovative future while addressing some of humanity’s biggest challenges.
About Us
Shaping the Future with Scalable Cell Culture Innovation
Our breakthrough 3D suspension culture platform
Enables mass production of high-quality cells without microcarriers or scaffolds—a game-changer for industries from biopharma to sustainable food production. By bringing cutting-edge science out of the lab and into large-scale production, we’re making advanced solutions commercially viable and accessible.
Accellta’s innovations are already powering advances in regenerative medicine and sustainable alternative ingredients. Our flexible, adaptable technology integrates seamlessly into existing manufacturing pipelines, accelerating timelines and unlocking new opportunities for our partners.
Located in the Technion in Haifa, Israel, Accellta is proud of its world-class facilities and highly professional team. We are committed to providing exceptional customer service and delivering on our promise of driving innovation in cell culture technology.
Management
During the past 19 years, Dr. Amit has dedicated her research work in laying the methodological groundwork for appropriate pluripotent stem cells culture. She conducted her Ph.D. degree in the Department of Medical Sciences at the Faculty of Medicine, Technion. Her thesis dealt with the isolation of human embryonic stem cells and their directed differentiation into blood cells.
In 1998 she joined Prof. Thomson at the University of Wisconsin where she was trained in growing and isolating embryonic stem cell lines. Upon her return to Israel she derived the first human embryonic stem cell line in Israel, third worldwide. Her areas of expertise are in the derivation of primary cell lines (adults, embryonic and fetal), culture medium development, cells mass production using dynamic systems, stem cells directed differentiation, and good manufacturing procedures.
Dr. Amit has published articles describing novel culture methods for culturing pluripotent stem cells, culturing stem cells in carrier-free suspension, as well as studies on stem cells directed differentiation methods. Her research experience is recognized with over 45 published papers which all together were cited about 10,000 times, as speaker with 30 national and international invited lectures, 15 patent families, and as co-investigator on grants in the field of pluripotent stem cells research. Some of these patents were used as the base for establishing Accellta, a stem cells company, where she serves as the CEO/CTO and co-founder.
Dr. Amit also wrote a book summarizing major culture methods for human pluripotent stem cells. On the academic side, she had trained over 10 graduate students and resident medical student research projects. In recent years, Michal serves as a Senior Lecturer at the Ephraim Katzir Department of Biotechnology Braude College.
Yael Garfinkel is an accomplished Chief Financial Officer with over a decade of experience in financial management, strategic planning, and accounting, with a focus on the biotechnology sector.
Since 2016, she has been the CFO of Accellta, where she oversees financial operations, prepares materials for investors, and plays a critical role in strategic decision-making, including negotiations and business planning.
Previously, Yael served as Group Controller at Bateman Engineering and Polygal Plastics Industries, where she led financial processes and supported major business initiatives.
She began her career at PwC, where she gained valuable auditing and financial reporting experience.
Yael holds a BA in Accounting and Economics from the University of Haifa and is a licensed CPA.
Eng. Roytblat serves as a Manager of Accellta’s cGMP clean rooms facility and Production. He also holds a role as Process development engineer and Projects Manager at Accellta (Scale-up process development in suspension for Spinners and Bioreactors), he is responsible for validation, calibration and maintenance of the GMP clean rooms facility, labs and equipment. Preventive maintenance management and execution. Additionally, he serves as Safety Trustee in charge of safety procedures and regulations.
Prior to Accellta, Mr. Roytblat served as R&D Research assistant at the Stem Cell Center, Faculty of Medicine, Technion.
Mr. Roytblat holds a B.Sc. Biotechnology Engineering (ORT Braude, Carmiel).
Dr. Shahar Ben-Shaul has extensive research experience in immunology, neuro-immunology, tissue engineering including cultured meat, stem cells, and molecular biology.
Shahar is responsible for all R&D activities ranging from planning the company roadmap to implementation of strategic decisions, in addition to understanding the clients’ needs, developing tailor-made solutions, and leading technology transfer to clients, domestic and abroad.
She graduated from the Faculty of Biomedical Engineering/Biotechnology at the Technion, conducting research in the Tissue and Stem Cell Engineering Laboratory under the supervision of Prof. Shulamit Levenberg.
Aviram Amit has been the Business Development Manager at Accellta since early 2023. In this role, Aviram oversees marketing, sales, and business development, guiding the company’s strategy from concept through execution.
Prior to joining Accellta, Aviram held leadership positions in international sales and marketing at companies including Seevix and 4IR Solutions. He also served as a Sales Manager at Merck, founded and managed an independent consulting business specializing in business development, and established two technology startups.
Aviram holds a B.Sc. in Chemical Engineering and Biotechnology from Ariel University and a Master’s Degree in Business Administration from The Open University.
Mrs. Rosentzwieg acts as Data Room and IP manager. Over the past 5 years Mrs. Rosentzwieg has been working as HR & Administration Manager and has been working in Accellta Ltd since its inception. Mrs. Rosentzwieg has an extensive HR experience in large organizations, vast experience in customer service and operations in a large telecommunication company. Mrs. Rosentzwieg holds a BA in communications and an MA degree in Human resources & Services.
Mrs. Tordjman serves as HR & Administration Manager of Accellta. For the last 5 years, Mrs. Tordjman worked at various fields of HR Department at the Strauss Group and Adam Milo Institute. She gained extensive experience in customer service and HR departments in recruiting, training and personal & groups diagnosing. She holds a BA in Behavioral Science from The Max Stern Yezreel Valley College.
Board of Directors
Noah Chong was trained as a corporate lawyer and admitted into the Dutch Bar Association in 2016. He practiced law at a leading international law firm where he represented primarily large cap companies. He graduated cum laude in corporate law at the University of Amsterdam (LL.B and LL.M). Mr. Chong joined Horizons Ventures in 2022.
Professor (Emeritus) Peretz Lavie – received his formal training in Sleep research and Sleep medicine at the University of Florida and at the University of California San Diego, and was a visiting professor at Harvard University in Boston. In 1975 he joined the Faculty of Medicine at the Technion – Israel the Center for Sleep Medicine. He was the Dean of Medicine (1993-1999) and Vice President for Resource Development and External Relations (2001-2008) and for 10 years served as the President of the Technion (2009-2019). Prof. Lavie is considered one of the founders of sleep medicine. He published more than 400 scientific articles and eight books in the field of sleep research and sleep disorders. His book “The Enchanted World of Sleep” has been translated into 15 languages. His research has won many prizes, including the Elkeles Prize from the Keren Kayemet LeIsrael for the best medical scientist (2001), the University of Pisa Sleep Award to Best Sleep Researcher in Europe (2004), the American Society of Sleep Research William Gruen Prize for innovative research (2006), and the EMET prize in medicine (2006), the most prestigious prize for academic achievements in Israel. He was the founder and co-founder of 5 companies that develop and produce medical devices for sleep medicine and cardiology and provide diagnostic services.
Seasoned tech executive with an eye for great ideas, a talent for spearheading innovation and a passion for building high-growth business.
Ms. Samler serves as the Chief Business Officer of Technion Research & Development Foundation Ltd. and Managing Director of T3 – Technion Technology Transfer, Rona oversees and leads the entire commercialization spectrum and is in charge of forming and shaping commercialization vehicles and policies enabling innovations to maximize their market potential. Additionally, in her capacity as CEO of AMIT- Alfred Mann Institute at the Technion Ltd., Technion’s evergreen investment arm in the life science arena, Rona is in charge of AMIT’s diversified investment portfolio, as well as the continuous identification of investment opportunities.
Prior to joining the Technion’s management team, Ms. Samler served as VP of Business Development at Ramot, Tel Aviv University’s technology transfer office, where she initiated and oversaw a long list of investments, licensing agreements and joint ventures with tech companies in Israel and worldwide.
Other positions include: Head of Business Development at Syneron Medical (NASDAQ: ELOS); CEO at Cupola Medical for the Offer Brothers Group’s Naiot Venture Accelerator; VP of Global Business at Colbar LifeScience (acquired by Johnson & Johnson in 2006 for $160 million).
Ms. Samler graduated summa cum laude in Chemistry at the Technion-Israel Institute of Technology and earned her MBA at Haifa University with highest distinction.